Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Olaratumab |
Trade Name | Lartruvo |
Synonyms | IMC-3G3 |
Drug Descriptions |
Lartruvo (olaratumab) is a monoclonal antibody that targets PDGFR-alpha and prevents ligand binding, potentially leading to decreased angiogenesis and reduced proliferation of tumor cells (PMID: 27291997). Lartruvo (olaratumab) in combination with doxorubicin is FDA approved for patients with soft tissue sarcoma (FDA.gov). |
DrugClasses | PDGFRA Antibody 2 |
CAS Registry Number | 1024603-93-7 |
NCIT ID | C79825 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Doxorubicin + Ifosfamide + Mesna + Olaratumab | Doxorubicin Ifosfamide Mesna Olaratumab | 0 | 1 |
Doxorubicin + Olaratumab | Doxorubicin Olaratumab | 0 | 2 |
Doxorubicin + Olaratumab + Sotigalimab | Doxorubicin Olaratumab Sotigalimab | 0 | 1 |
Doxorubicin + Olaratumab + Trabectedin | Doxorubicin Olaratumab Trabectedin | 0 | 1 |
Gemcitabine + Nab-paclitaxel + Olaratumab | Gemcitabine Nab-paclitaxel Olaratumab | 0 | 1 |
Olaratumab | Olaratumab | 0 | 5 |
Olaratumab + Pembrolizumab | Olaratumab Pembrolizumab | 0 | 1 |